Gilead Sciences: Hepatitis C Still Disappointing?
August 26, 2016 at 10:05 AM EDT
Citigroup's Robyn Karnauskas and Mohit Bansal note that sales of Gilead Sciences' ( GILD ) hepatitis-C treatments look to be coming in below investor expectations. They explain:
